Life Science

COX-1 and COX-2 catalyze the production of the PG and TX precursor PGH2. COX-2 is primarily responsible for the biosynthesis of PGs under acute inflammatory conditions.

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

A selective inhibitor of PDGFR&beta and PDGFR&alpha kinases (IC₅₀s = 1 and 10 nM, respectively) antiangiogenic and antitumor activity in several in vivo tumor models.

A selective inhibitor of PDGFR&beta and PDGFR&alpha kinases (IC₅₀s = 1 and 10 nM, respectively) antiangiogenic and antitumor activity in several in vivo tumor models.

A selective inhibitor of PDGFR&beta and PDGFR&alpha kinases (IC₅₀s = 1 and 10 nM, respectively) antiangiogenic and antitumor activity in several in vivo tumor models.